{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:07Z","timestamp":1790683807933,"version":"4.1.0"},"reference-count":13,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Background: Hereditary Angioedema is an autosomal dominant disorder caused by a lack or decrease in the function of the C1 inhibitor. It is a rare disease with low prevalence. Treatment focuses on symptom relief and short- and long-term prevention of acute attacks.\nCase report: 53-year-old male patient, with recurrent edema in the face, feet, scrotum, associated with abdominal pain since he was 20 years old. Patient has a history of hereditary angioedema in first-degree relatives of consanguinity. Laboratory tests showed low levels of plasma protein (antigenic), functional C1-INH and C4. The patient received several medical treatments. Given the recurrence of symptoms, prophylactic management with Lanadelumab was indicated. However, the patient presented erythema and induration at the application site with subsequent secondary generalized pruritus. For this reason, prophylaxis was suspended.\nConclusion: This case of hereditary angioedema type 1 presents the difficulty in the treatment and the relapse of the patient after trying various therapies, as well as the finding of the adverse effect presented to the prophylactic medication with Lanadelumab, which has been poorly documented in the literature medical worldwide.\nKeywords: Hereditary angioedema type 1; Plasmatic protein; Prophylactic management; Adverse event; Lanadelumab.<\/jats:p>","DOI":"10.29262\/ram.v71i4.1323","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T03:01:06Z","timestamp":1735268466000},"page":"264-267","source":"Crossref","is-referenced-by-count":2,"title":["Angioedema hereditario tipo 1, limitaciones de la terapia profil\u00e1ctica con lanadelumab: a prop\u00f3sito de un caso","Hereditary angioedema type 1, limitations for prophylactic therapy with Lanadelumab: Regarding a case"],"prefix":"10.29262","volume":"71","author":[{"given":"Martha Lizeth","family":"Fonseca-Becerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Sebastian","family":"Betancur-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy Camila","family":"Perilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11808","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"59873","unstructured":"Zafra H. Hereditary Angioedema: A Review. WMJ 2022; 121 (1): 48-53."},{"key":"59874","doi-asserted-by":"crossref","unstructured":"Rosi-Schumacher M, Shah SJ, Craig T, Goyal N. Clinical manifestations of hereditary angioedema and a systematic review of treatment options. Laryngoscope Investig Otolaryngol. 2021; 6 (3): 394-403. doi: 10.1002\/lio2.555","DOI":"10.1002\/lio2.555"},{"key":"59875","doi-asserted-by":"crossref","unstructured":"Nieto S, Madrigal I, Contreras F, Vargas ME. Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns. World Allergy Organ J 2023; 16 (9): 100812. doi: 10.1016\/j.waojou.2023.100812","DOI":"10.1016\/j.waojou.2023.100812"},{"key":"59876","doi-asserted-by":"crossref","unstructured":"Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med 2020; 382 (12): 1136-1148. doi: 10.1056\/NEJMra1808012","DOI":"10.1056\/NEJMra1808012"},{"key":"59877","doi-asserted-by":"crossref","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema. The 2021 revision and update. Allergy. 2022; 77 (7): 1961-1990. doi: 10.1111\/all.15214","DOI":"10.1111\/all.15214"},{"key":"59878","doi-asserted-by":"crossref","unstructured":"Sinnathamby ES, Issa PP, Roberts L, et al. Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology. Adv Ther 2023; 40 (3): 814-827. doi: 10.1007\/s12325-022-02401-0","DOI":"10.1007\/s12325-022-02401-0"},{"key":"59879","doi-asserted-by":"crossref","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract 2021; 9 (1): 132-150.e3. doi: 10.1016\/j.jaip.2020.08.046","DOI":"10.1016\/j.jaip.2020.08.046"},{"key":"59880","doi-asserted-by":"crossref","unstructured":"Caballero T. Treatment of Hereditary Angioedema. J Investig Allergol Clin Immunol. 2021; 31 (1): 1-16. doi: 10.18176\/jiaci.0653","DOI":"10.18176\/jiaci.0653"},{"key":"59881","doi-asserted-by":"crossref","unstructured":"Bova M, Valerieva A, Wu MA, Senter R, et al. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy. Drug Des Devel Ther 2019; 13: 3635-3646. doi: 10.2147\/DDDT.S192475","DOI":"10.2147\/DDDT.S192475"},{"key":"59882","doi-asserted-by":"crossref","unstructured":"Lumry WR, Weller K, Magerl M, et al. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy 2021; 76 (4): 1188-1198. doi: 10.1111\/all.14680","DOI":"10.1111\/all.14680"},{"key":"59883","doi-asserted-by":"crossref","unstructured":"Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy 2022; 77 (3): 979-990. doi: 10.1111\/all.15011","DOI":"10.1111\/all.15011"},{"key":"59884","doi-asserted-by":"crossref","unstructured":"Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test (AECT)-A Patient-Reported Outcome Instrument for Assessing Angioedema Control. J Allergy Clin Immunol Pract 2020; 8 (6): 2050-2057.e4. doi: 10.1016\/j.jaip.2020.02.038","DOI":"10.1016\/j.jaip.2020.02.038"},{"key":"59885","doi-asserted-by":"crossref","unstructured":"Kulthanan K, Chularojanamontri L, Rujitharanawong C, Weerasubpong P, et al. Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change. Health Qual Life Outcomes 2019; 17 (1): 160. doi: 10.1186\/s12955-019-1229-3","DOI":"10.1186\/s12955-019-1229-3"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1323\/2247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1323\/2314","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1323\/2247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:16:13Z","timestamp":1744215373000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,26]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v71i4.1323","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}